期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 38, 期 8, 页码 864-886出版社
WILEY
DOI: 10.1111/apt.12460
关键词
-
资金
- Danone
- Almirall
- Shire
- AstraZeneca
- Canadian Association for Gastroenterology
- Metagenics
- Yakult
- BioProx
- Danisco
- Kemin
- Lesaffre
- Roquette
- Vesale Pharma
- Norgine
- Abbott
- GlaxoSmithKline AEBE
- Pfizer Hellas A.E./Pfizer Inc.
- European Commission
- ESPCG
- ZON MW, the Dutch Research Institute
- Danone (Paris, France)
- Medical Research Council [MR/K02325X/1] Funding Source: researchfish
BackgroundEvidence suggests that the gut microbiota play an important role in gastrointestinal problems. AimTo give clinicians a practical reference guide on the role of specified probiotics in managing particular lower gastrointestinal symptoms/problems by means of a systematic review-based consensus. MethodsSystematic literature searching identified randomised, placebo-controlled trials in adults; evidence for each symptom/problem was graded and statements developed (consensus process; 10-member panel). As results cannot be generalised between different probiotics, individual probiotics were identified for each statement. ResultsThirty seven studies were included; mostly on irritable bowel syndrome [IBS; 19 studies; treatment responder rates: 18-80% (specific probiotics), 5-50% (placebo)] or antibiotic-associated diarrhoea (AAD; 10 studies). Statements with 100% agreement and high' evidence levels indicated that: (i) specific probiotics help reduce overall symptom burden and abdominal pain in some IBS patients; (ii) in patients receiving antibiotics/Helicobacter pylori eradication therapy, specified probiotics are helpful as adjuvants to prevent/reduce the duration/intensity of AAD; (iii) probiotics have favourable safety in patients in primary care. Items with 70-100% agreement and moderate' evidence were: (i) specific probiotics help relieve overall symptom burden in some patients with diarrhoea-predominant IBS, and reduce bloating/distension and improve bowel movement frequency/consistency in some IBS patients and (ii) with some probiotics, improved symptoms have led to improvement in quality of life. ConclusionsSpecified probiotics can provide benefit in IBS and antibiotic-associated diarrhoea; relatively few studies in other indications suggested benefits warranting further research. This study provides practical guidance on which probiotic to select for a specific problem.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据